111 related articles for article (PubMed ID: 19854838)
1. Use of erythropoietins in patients with renal transplants.
Treleaven DJ; Clase CM
BMJ; 2009 Oct; 339():b3825. PubMed ID: 19854838
[No Abstract] [Full Text] [Related]
2. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
Singh AK
J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
[No Abstract] [Full Text] [Related]
3. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study.
Heinze G; Kainz A; Hörl WH; Oberbauer R
BMJ; 2009 Oct; 339():b4018. PubMed ID: 19854839
[TBL] [Abstract][Full Text] [Related]
4. The normal HCT trial re-revisited: what were the actual findings?
Besarab A; Bolton WK; Nissenson AR; Schwab SJ
Kidney Int; 2012 Jul; 82(2):242; author reply 242-3. PubMed ID: 22743566
[No Abstract] [Full Text] [Related]
5. Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease.
Vaziri ND; Zhou XJ
Nephrol Dial Transplant; 2009 Apr; 24(4):1082-8. PubMed ID: 18987263
[No Abstract] [Full Text] [Related]
6. Erythropoietin: high profile, high scrutiny.
Crawford J
J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
[No Abstract] [Full Text] [Related]
7. Chronic kidney disease anemia management: what should be done?
Szczech LA
Blood Purif; 2011; 31(1-3):186-8. PubMed ID: 21228588
[TBL] [Abstract][Full Text] [Related]
8. Full results on risks of epoetin emerge 14 years after major dialysis study.
Epstein K
BMJ; 2012 May; 344():e3535. PubMed ID: 22619221
[No Abstract] [Full Text] [Related]
9. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
10. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
11. Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.
Winkelmayer WC
J Am Soc Nephrol; 2011 Jan; 22(1):1-2. PubMed ID: 21164031
[No Abstract] [Full Text] [Related]
12. [Renal anemia treatment and outcome of patients with chronic kidney disease].
Kuragano T; Nakanishi T
Nihon Jinzo Gakkai Shi; 2009; 51(7):852-6. PubMed ID: 19928557
[No Abstract] [Full Text] [Related]
13. FDA panel scrutinizes safety of anti-anemia drugs.
Randal J
J Natl Cancer Inst; 2004 Jul; 96(14):1061. PubMed ID: 15265966
[No Abstract] [Full Text] [Related]
14. New limits advised for anemia drugs.
Mitka M
JAMA; 2007 Jun; 297(22):2464. PubMed ID: 17565074
[No Abstract] [Full Text] [Related]
15. A physician's perseverance uncovers problems in a key nephrology study.
Fishbane S; Wish JB
Kidney Int; 2012 Jul; 82(2):135-7. PubMed ID: 22743565
[TBL] [Abstract][Full Text] [Related]
16. Anemia normalization in patients with type 2 diabetes and chronic kidney disease: results of the NEPHRODIAB2 randomized trial.
Villar E; Lièvre M; Kessler M; Lemaître V; Alamartine E; Rodier M; François M; Zaoui P; Moranne O; Choukroun G; Guerraoui A; Jolivot A; Janin G; Branger B; Heng AE; Boudray C; Bissery A; Rabilloud M; Pouteil-Noble C
J Diabetes Complications; 2011; 25(4):237-43. PubMed ID: 21601481
[TBL] [Abstract][Full Text] [Related]
17. Amgen's point of view on epoetins.
Seidenberg B; Perlmutter RM
Lancet Oncol; 2004 Apr; 5(4):206-7. PubMed ID: 15050950
[No Abstract] [Full Text] [Related]
18. Anemia therapy in kidney disease. What research reveals about ESA medication safety.
Johns Hopkins Med Lett Health After 50; 2010 Nov; 22(9):1-2, 7. PubMed ID: 21066834
[No Abstract] [Full Text] [Related]
19. An ongoing study of anemia correction in chronic kidney disease.
Pfeffer MA;
N Engl J Med; 2007 Mar; 356(9):959-61. PubMed ID: 17329707
[No Abstract] [Full Text] [Related]
20. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Walker RG
Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
[No Abstract] [Full Text] [Related]
[Next] [New Search]
